Skip to main content
CABLIVI (caplacizumab-yhdp) logo

Support for your patients from HemAssist


HemAssist Sanofi Support logo

We complement the support you provide your CABLIVI patients and their caregivers with access to treatment, education, and financial assistance from Sanofi.

Decorative wallet icon

Financial assistance

Every person’s situation is different, which is why we work directly with patients to help identify the financial assistance programs for which they may be eligible.

Decorative book icon

Treatment education

We can help your patients understand more about aTTP/iTTP and CABLIVI, as well as offer supplemental injection training and tips to help them start and stay on track with treatment from hospital to home.

Decorative key icon

Access to treatment

From navigating insurance coverage to assisting with reimbursement, our team works with you and your patients to get them started on CABLIVI as efficiently as possible.

Financial assistance:

Copay Assistance Program*

HemAssist Sanofi Support may be able to help eligible CABLIVI patients gain access to treatment for as little as $0 with annual maximum savings up to $25,000 with no income caps.

*Not valid if the patient is utilizing a state or federally funded health insurance program such as Medicare (including Medicare Part D), Medicaid, Medigap, VA, DoD, TRICARE®, state pharmaceutical assistance program, etc. to pay in part or in full for their CABLIVI prescription. Not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Copay Program at any time without notice. Savings by patients may vary depending on their out-of-pocket costs. The program is intended to help patients afford their CABLIVI prescription. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms.

Patient Assistance Program

HemAssist’s Patient Assistance Program may be available to help with out-of-pocket medication costs for eligible uninsured and underinsured patients.

Bridge Program

If patients experience a loss of coverage or are facing other insurance barriers, the Bridge Program may be able to help with access to CABLIVI.

Claims for free products dispensed through the Patient Assistance or Bridge Programs shall not be submitted to any third-party payer, public or private (e.g. private insurance, Medicaid, Medicare, VA, DoD, TRICARE®, or similar federal or state programs) for reimbursement. All Programs not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.

Team members

Field Reimbursement Managers (FRMs)

Our FRMs can help you navigate insurance coverage and provide reimbursement education and solutions.

Portrayal of a smiling man sitting at a desk wearing a headset

Case Managers

For patients: Case Managers assist with navigating insurance coverage and identifying the financial support patients may be eligible for.

 

For HCPs: Our dedicated Case Managers will provide you with personalized insurance investigations and answer your specific questions about financial assistance options for eligible patients. They can help coordinate treatment shipments and assist with reimbursements.

HemAssist team member sitting at a desk with a headset

Clinical Educators (CEs)

For patients: CEs are your patient’s point of contact for CABLIVI education, tips, supplemental injection training, and ongoing support.

 

For HCPs: CEs can answer questions about aTTP/iTTP and CABLIVI and can provide helpful support to your patients including CABLIVI education, treatment tips, and supplemental injection training. 

Here for you and your patients

Learn more about how we work with you and your patients to help them access, get started, and stay with treatment as prescribed.

Support starts with enrollment

It takes just a few steps.
   

For questions about HemAssist Sanofi Support for Cablivi, call 1-833-723-5463 Monday – Friday 8 AM to 7 PM ET.

Share with your patients with aTTP/iTTP the opportunity to join an educational webinar hosted by a Sanofi Clinical Educator.

CABLIVI (caplacizumab-yhdp) Patient Enrollment Form thumbnail

CABLIVI HemAssist Patient Enrollment Form

Enroll patients in HemAssist Sanofi Support for access to specialty pharmacy services, financial assistance, and supplemental injection training

CABLIVI (caplacizumab-yhdp) Patient Solutions thumbnail

HemAssist Sanofi Support

Learn more about the support offered through HemAssist Sanofi Support.

  
  

Download symbol

Access and download resources to share with your patient

From hospital to home symbol

Ease the transition from hospital to home

INDICATIONS

CABLIVI (caplacizumab-yhdp) is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:

CABLIVI is contraindicated in patients with a previous severe hypersensitivity reaction to caplacizumab-yhdp or to any of its excipients. Hypersensitivity reactions have included urticaria.

WARNINGS AND PRECAUTIONS:

Hemorrhage:

  • CABLIVI increases the risk of bleeding. In clinical studies, severe bleeding adverse reactions of epistaxis, gingival bleeding, upper gastrointestinal hemorrhage, and metrorrhagia were each reported in 1% of subjects. Overall, bleeding events occurred in approximately 58% of patients on CABLIVI versus 43% of patients on placebo.
  • In the postmarketing setting cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI.
  • The risk of bleeding is increased in patients with underlying coagulopathies (e.g. hemophilia, other coagulation factor deficiencies). It is also increased with concomitant use of CABLIVI with drugs affecting hemostasis and coagulation.
  • Avoid concomitant use of CABLIVI with antiplatelet agents or anticoagulants. If clinically significant bleeding occurs, interrupt use of CABLIVI. Von Willebrand factor concentrate may be administered to rapidly correct hemostasis. If CABLIVI is restarted, monitor closely for signs of bleeding.
  • Withhold CABLIVI for 7 days prior to elective surgery, dental procedures or other invasive interventions. If emergency surgery is needed, the use of von Willebrand factor concentrate may be considered to correct hemostasis. After the risk of surgical bleeding has resolved, and CABLIVI is resumed, monitor closely for signs of bleeding. 

ADVERSE REACTIONS:

The most common adverse reactions (>15% of patients) were epistaxis (29%), headache (21%) and gingival bleeding (16%).

CONCOMITANT USE OF ANTICOAGULANTS OR ANTIPLATELET AGENTS:

Concomitant use of CABLIVI with any anticoagulant or antiplatelet agent may increase the risk of bleeding. Avoid concomitant use when possible. Assess and monitor closely for bleeding with concomitant use.

PREGNANCY:

There are no available data on CABLIVI use in pregnant women to inform a drug associated risk of major birth defects and miscarriage.

  • Fetal/neonatal adverse reactions: CABLIVI may increase the risk of bleeding in the fetus and neonate. Monitor neonates for bleeding.
  • Maternal adverse reactions: All patients receiving CABLIVI, including pregnant women, are at risk for bleeding. Pregnant women receiving CABLIVI should be carefully monitored for evidence of excessive bleeding.

INDICATIONS

IMPORTANT SAFETY INFORMATION

© 2025 Sanofi. All rights reserved. CABLIVI, HemAssist, and Sanofi are trademarks of Sanofi or an affiliate. All other trademarks are the property of their respective owners. MAT-US-2024234-v7.0-08/2025 Last Updated: August 2025.